

# **National Collaborating Centre for Women's and Children's Health**

**2<sup>nd</sup> Feverish Illness in Children Guideline Development Group Meeting  
9<sup>th</sup> February 2012, 10am – 4.30pm at RCOG**

**Present:**

Richard Bowker (RB)	Consultant Paediatrician
John Crimmins (JC)	General Practitioner
Penny McDougall (PMD)	Nurse
Debra Quantrill (DQ)	Lay member
Martin Richardson (MR)	Chair
Andrew Riordan (AR)	Paediatric infectious diseases expert
Damian Roland (DR)	Emergency medicine expert

**NCC staff:**

Jiri Chard (JAC)	Senior Research Fellow
Hannah Rose Douglas (HRD)	Senior Health Economist
Ella Fields (EF)	Research Fellow (afternoon only)
Zipporah Iheozor-Ejiofor (ZIE)	Research Assistant
Stephen Murphy (SM)	Clinical Co-Director (Children's Health)
Nitara Prasannan (NP)	Research Assistant (afternoon only)
Cristina Visintin (CV)	Project Manager

**In attendance:**

Ben Doak (BD)	Guideline Commissioning Manager, NICE (afternoon only)
---------------	--

**Apologies:**

Leah Bowen (LB)	Lay member
Ed Pursell (EP)	Nurse

---

## **1. Welcome, housekeeping, introductions and apologies**

MR welcomed everyone to the meeting. Apologies were received as listed above.

MR asked the group for any new declarations of interest. No new declarations of interest were received from the GDG members. It was agreed that no declared interests warranted exclusion of any GDG members from discussions of evidence or formulation of recommendations.

After minor corrections the minutes of the previous meeting were accepted as an accurate record of that meeting.

MR briefed the group on the objectives of the current meeting.

**2. What Procalcitonin (PCT) and C-reactive Protein (CRP) are and summary of 2007 guideline**

AR gave an introduction of what PCT and CRP are, and a reminder of what was included in the 2007 guideline on this subject.

**3. Predictive value of PCT and/or CRP**

ZIE presented evidence for the review questions on the predictive value of PCT and/or CRP markers. During the presentations the group had an opportunity to ask questions.

**Break**

MR led the GDG discussion on the evidence for the predictive value of PCT and/or CRP markers.

**Lunch break**

*BD joined the meeting*

The GDG continued the discussion use of CRP and PCT. Based on the evidence presented and discussion the GDG were able to draft recommendations on use of PCT and CRP for the management of feverish illness in children.

*ZIE left the meeting*

**4. Discussion about antipyretic treatment**

JC gave a brief up-date on the ongoing work on the antipyretic treatment.

*EF and NP joined the meeting*

**5. Health economic**

HRD gave an update on health economic analysis, in particularly on the predictive value of PCT and/or PCT markers and the use of antipyretics treatment. The GDG agreed that it is going to be difficult to acquire data for a health economic model.

**6. The predictive value of symptoms and signs, alone or in combination, as initial indications of serious illness**

EF gave an up-date the on the ongoing work on predictive value of symptoms and signs, alone or in combination, as initial indications of serious illness.

**7. Next steps**

CV informed the GDG about the timeline of the guideline development process and the dates for additional GDG meetings, two in the development period (12<sup>th</sup> July 2012 and 20<sup>th</sup> September 2012) and one after consultation (30<sup>th</sup>/31<sup>st</sup> January 2013).

**8. Any other business**

There was no other business. MR thanked the participants for attending and closed the meeting. The next meeting will be held on 8<sup>th</sup> march 2012 at the RCOG.

**Signed:**..... **Date:**.....  
**Martin Richardson, GDG Chair**

**Signed:**..... **Date:**.....  
**Stephen Murphy, Clinical Co-Director (Children's Health)**